Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia

Metabolism: Clinical and Experimental

Volumn 51, Issue 8, 2002, Pages 976-980

  Goldammer, Andreas ^a   Wiltschnig, Stefanie ^a   Heinz, Gottfried ^a   Jansen, Martin ^a   Stulnig, Thomas ^a   Hörl, Walter H ^a   Derfler, Kurt ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; APHERESIS; ARTERY DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; FLATULENCE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MYALGIA; MYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 0036345274     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.34016     Document Type: Article

References (34)

1. Improvement of coronary vasodilatation capacity through single LDL-apheresis
2. Current status of low-density lipoprotein-apheresis for the therapy of severe hyperlipidemia
3. Direct adsorption of lipoproteins (DALI) from whole blood: First long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia
4. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis
5. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolemia
6. Familial Hypercholesterolaemia Regression Study: A randomised trial of low-density-lipoprotein apheresis
7. Apheresis technology for prevention and regression of atherosclerosis: An overview
8. Statins: Within-group comparisons, statin escape and combination therapy
9. Profiling risk and new therapeutic interventions: Looking ahead
10. Drug and alternative therapies for hyperlipidemia
11. Issue of lower limit for LDL cholesterol unresolved
12. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
13. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study
14. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
15. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
16. Comparative dose efficacy study of atorvastatin with that of lovastatin, pravastatin, simvastatin, and fluvastatin in patients with hypercholesterolemia: The CURVES study
17. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL-apheresis
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
19. Low-density lipoprotein apheresis does not increase plasma lipid peroxidation products in vivo
20. A rapid and precise determination of fibrinogen and its cleavage products
21. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
22. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
23. Risk factor modification: Rationale for management of dyslipidemia
24. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy
25. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomized, double-blind trial
26. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis
27. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy
28. Coronary plaque disrupture
29. Long-term efficacy of low-density-lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia
30. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
31. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia
32. Statins and fibrinogen
33. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL-apheresis treatment
34. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia